Media

Our latest news, announcements and multimedia resources

Latest news

January 6, 2025

Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

December 20, 2024

Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody

December 19, 2024

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

December 18, 2024

Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

December 17, 2024

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

December 16, 2024

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab

January 2, 2025

Merck honors the life and legacy of President Jimmy Carter

November 20, 2024

Merck Foundation Heightens Focus on Advancing Equity in Cardiac Care Across the U.S.

September 26, 2024

Merck Provides Update on FDA’s Oncologic Drugs Advisory Committee Meeting Discussion of PD-L1 Expression Levels in Certain Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer Indications

August 22, 2024

FDA’s Oncologic Drugs Advisory Committee to Discuss PD-L1 Expression Thresholds in Certain Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer Indications for Immune Checkpoint Inhibitors in the U.S., Including KEYTRUDA® (pembrolizumab)

August 19, 2024

Merck Reports Strong Momentum in Expanding and Enabling Access to Health Care, Driving Sustainability and Operating Responsibly in 2023/2024 Impact Report

CDC’s ACIP Unanimously Votes to Add Merck and Sanofi’s Pediatric Hexavalent Combination Vaccine to its Preferential Recommendation to Help Prevent Invasive Hib Disease in American Indian and Alaska Native Infants

Media resources

Bright light tubes against a silver wall

News releases

Read our latest news releases.

Underside of a staircase

Company statements

Read our latest company statements.

Man reviewing post-it-notes on glass wall

Media library

Access videos, logos, photos and infographics.

Media contacts

Global media relations

+1 908-740-5633

mediarelations@merck.com

Get to know us through our stories

Everything we do, in and out of the laboratory, is based on our deep appreciation for life. Get a glimpse of what it’s like on the inside through our stories.

Scientist reviewing test tubes

We are driven by a single purpose

We use the power of leading-edge science to save and improve lives around the world.

Learn more about our company

Person reviewing product pipeline on their smartphone

Investor relations

Find our latest financials, events & presentations, news, stock information and investor contacts.

Visit investor relations

Two employees in the lobby on their laptops

Company fact sheet

Access company information including stock ticker, official company names, description, and more.

See company fact sheet

Unsubscribe from email alerts